The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results

Cardim, Nuno; Brito, Dulce; Lopes, Luís Rocha; Freitas, António; Araújo, Carla; Belo, Adriana; Gonçalves, Lino; Mimoso, Jorge; Olivotto, Iacopo; Elliott, Perry; Madeira, Hugo

doi:10.1016/j.repc.2017.08.005

Cited by 41 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the incidence of HCM was still higher in males, with a male-to-female ratio of about 2:1. The male predominance in HCM has been previously reported [13][14][15][16]. Given the autosomal dominant inheritance, the male-to-female ratio should be 1:1.…”

Section: Discussionmentioning

confidence: 85%

“…In the last 20 years, many retrospective and/or observational cohort studies have found that normal life expectancy is expected in most patients with HCM, without the functional disability of disease-associated clinical events, nor the necessity for therapeutic interventions [2,7,20]. As supporting evidence, the average age of the first diagnosis has markedly increased more than 60 years old in recently published studies [13,[16][17][18]. Furthermore, a communitybased cohort study without selection bias caused by selected referral to the tertiary care centers showed that a quarter of HCM patients were more than 75 years old [7].…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study

et al. 2020

View full text Add to dashboard Cite

Temporal trends of the prevalence and incidence of hypertrophic cardiomyopathy (HCM) have not been well established in Asian populations. Using the Korean National Health Insurance Services database, we identified patients with a confirmed diagnosis of HCM between 2010 and 2016. The annual prevalence and incidence of HCM, and their clinical characteristics were investigated. The prevalence of HCM has increased from 0.016% (n = 6313) in 2010 to 0.031% (n = 13,035) in 2016. During a 7-year period, 13,229 patients were newly diagnosed with HCM. The incidence rate increased from 4.15 (per 100,000 personyears) in 2010 to 5.6 in 2016. The prevalence and incidence of HCM increased with age and peaked during the 70s, with male predominance in all age groups. Chest pain is the most frequent clinical presentation followed by shortness of breath and syncope. Hypertension and dyslipidemia were the two most common comorbidities. Heart failure and atrial fibrillation was diagnosed in about 1/3 and 1/4 of patients with HCM, respectively. The prevalence and incidence of HCM gradually increased from 2010 to 2016, possibly due to heightened recognition of the disease. Given the progressively high incidence of HCM with age and high prevalence of coexisting modifiable risk factors, continued efforts are required to increase awareness regarding HCM-related symptoms and potential complications. OPEN ACCESS Citation: Moon I, Lee S-Y, Kim H-K, Han K-D, Kwak S, Kim M, et al. (2020) Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide populationbased cohort study. PLoS ONE 15(1): e0227012.Categorical variables (frequencies and percentages) were compared using the χ 2 test or Fisher's exact test, and continuous variables (mean ± standard deviation) were analyzed using the Prevalence and incidence of hypertrophic cardiomyopathy PLOS ONE | https://doi.org/10.1371/journal.pone.0227012 January 13, 2020 2 / 10 Handok Pharm, Dae-Woong Pharm, Yuhan, Hanmi, ChongKunDang Pharm and Norvatis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors have nothing to disclose.Fig 1. The prevalence of HCM from 2010 to 2016. A. Temporal trend of the prevalence of HCM stratified by gender. B. Age-stratified temporal trend of HCM prevalence. HCM = hypertrophic cardiomyopathy.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 97%

Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…(only 6% for bradyarrhythmia) and 13%, respectively, over an average follow up of 3.3 years. 22 Our study found much higher CIED implantation rates during a shorter period following ASA; 14% and 11% received PPM or ICD during the index hospitalization, respectively, and another 1% underwent CIED implantation over the ensuing 30 days. These disparate findings resulted from a slightly higher than average PPM implantation rate, failure of most prior studies to report index hospitalization ICD implantation rates 4,13,14 and much higher observed ICD implantation rates than anticipated.…”

Section: Discussionmentioning

confidence: 47%

“…A recent analysis from the Euro‐ASA registry observed PPM and ICD placement in 13% and 5% of HCM patients, respectively, over 5 years of follow‐up after ASA 21 . Similarly, the Portuguese Registry of Hypertrophic Cardiomyopathy recently reported PPM and ICD rates of 9% (only 6% for bradyarrhythmia) and 13%, respectively, over an average follow up of 3.3 years 22 . Our study found much higher CIED implantation rates during a shorter period following ASA; 14% and 11% received PPM or ICD during the index hospitalization, respectively, and another 1% underwent CIED implantation over the ensuing 30 days.…”

Section: Discussionmentioning

confidence: 97%

Cardiac implantable electronic device placement following alcohol septal ablation for hypertrophic cardiomyopathy in the United States

Lam

Naidu

Kolte

et al. 2020

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Background: Cardiac implantable electronic devices (CIED) are sometimes required after alcohol septal ablation (ASA) for hypertrophic cardiomyopathy (HCM). The primary objectives of this study were to characterize the incidence, timing, and predictors of CIED placement after ASA for HCM. Methods: Patients were identified from the 2010-2015 Nationwide Readmissions Databases. Incidence, timing and independent predictors of CIED placement, as well as 30-day readmission rates were examined. Results: There were 1296 patients (national estimate = 2864) with HCM who underwent ASA. CIED were implanted in 322 (25% overall; 14% permanent pacemaker, 11% implantable cardioverter defibrillator) during the index hospitalization. Of these, 21%, 23%, 21%, and 18% occurred on postprocedure day 0, 1, 2, and 3, respectively. Only 17 (1.3%) patients underwent CIED implantation between discharge and 30-day follow up. Independent predictors of index hospitalization CIED implantation included older age, diabetes, heart failure, nonelective index hospital admission and hospitalization at a privately owned hospital. Nonelective 30-day readmission rates among those who did and did not undergo CIED placement during their index hospitalization, were 6.8% and 7.9%, respectively (p = .53); median time to readmission was also similar between groups. Conclusions: One in four HCM patients undergoing ASA underwent CIED implantation during their index hospitalization; nearly 2/3rd during the first 48 h postprocedure. Private hospital ownership independently predicted CIED placement. More data are needed to better understand the unexpectedly high rates of CIED placement, earlier than anticipated timing of implantation and differential rates by hospital ownership.

show abstract

“…This registry shows that there are important differences in HCM management between guidelines and clinical practice, which was also demonstrated in other registries. 43,44 This can be the result of different HCM clinical courses representing the heterogeneous spectrum of HCM. Finally, these data reinforce the importance of using clinical registries as an important source of information that should be used to inform practice but also to influence the writing of the guidelines.…”

Section: Cardiomyopathies and Valvular Heart Diseasementioning

confidence: 99%